Skip to main content
. 2016 May 13;7(25):37882–37892. doi: 10.18632/oncotarget.9352

Figure 3. Analysis of high clonal V-J combinations.

Figure 3

(AD) The 10 most frequent V-J combinations of PBMCs from UPN1 (A), UPN2 (B), UPN3 (C) and UPN4 (D) at baseline and after 2 cycles of decitabine therapy are indicated in color; the remaining V-J combinations are grouped in white.